Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) – a single-center experience

The objective of the study was to evaluate the efficacy of ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). The data of 104 patients transplanted at the Department of Hematology Medical University of Lodz between 2005 a...

Full description

Saved in:
Bibliographic Details
Published in:Advances in medical sciences 2012-06, Vol.57 (1), p.118-123
Main Authors: Wolska, A, Robak, T, Szmigielska-Kaplon, A, Pluta, A, Kopka, P, Wierzbowska, A
Format: Article
Language:English
Subjects:
Adult
Aged
ASCT
ciprofloxacin
Ciprofloxacin - therapeutic use
Female
fluoroquinolones
Fluoroquinolones - therapeutic use
Humans
infection
Male
melphalan
Melphalan - therapeutic use
Middle Aged
multiple myeloma
Multiple Myeloma - drug therapy
prophylaxis
Retrospective Studies
Transplantation, Autologous
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c437t-ac28147a885e98097a6b0e00927a2d8d4b4292956585b0335deac3e56d617c33
cites cdi_FETCH-LOGICAL-c437t-ac28147a885e98097a6b0e00927a2d8d4b4292956585b0335deac3e56d617c33
container_end_page 123
container_issue 1
container_start_page 118
container_title Advances in medical sciences
container_volume 57
creator Wolska, A
Robak, T
Szmigielska-Kaplon, A
Pluta, A
Kopka, P
Wierzbowska, A
description The objective of the study was to evaluate the efficacy of ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). The data of 104 patients transplanted at the Department of Hematology Medical University of Lodz between 2005 and 2008 were analyzed. The cohort was divided into two groups depending on the administered ciprofloxacin prophylaxis. Conditioning regimens did not differ significantly among the groups. Multiple myeloma was the main indication for ASCT in both groups. Ciprofloxacin prophylaxis resulted in a statistically significant reduction of duration of intravenous (IV) antibiotic treatment in the group with prophylaxis (p=0.01). The trend has been observed towards lower prevalence of infectious episodes in the prophylaxis group. Positive blood cultures were similar in both groups with no significant resistance to ciprofloxacin. These data demonstrate that ciprofloxacin prophylaxis is beneficial for patients treated with ASCT following high dose chemotherapy regimen, in terms of the intravenous antibiotics usage. This advantage directly translates into economic benefit and may also induce less bacterial resistance due to less exposure to antibiotics.
doi_str_mv 10.2478/v10039-012-0004-z
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020828878</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S189611261460119X</els_id><sourcerecordid>1020828878</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-ac28147a885e98097a6b0e00927a2d8d4b4292956585b0335deac3e56d617c33</originalsourceid><addsrcrecordid>eNp9kbtuFDEUhkcIRC7wADTIEk1SGHyZi0cUUbTiJkWiYHvLa5-dcTRjD7Yn7KbiHSh4P54EbyYghASV_-I7v_9z_qJ4RslLVjbi1Q0lhLeYUIYJISW-fVAcU9EKXBLCHt7pGlPK6qPiJMZrQmpWE_K4OGKM11lXx8X3lZ2C3w5-p7R1KOup3w9qZyPa-oAmlSy4FNHsDITOW9eh3nY9Nj4C0j2MPvUQ1LRHyhmk5uQH3_k5ophgRBqGAaWgXJwG5VI28w6dXX5arc_Rj6_fkEIxOw6Adf4EAoLdBCF_qOFJ8WirhghP79_TYv32zXr1Hl99fPdhdXmFdcmbhJVmgpaNEqKCVpC2UfWGACEtaxQzwpSbkrWsrepKVBvCeWVAaQ5VbWraaM5Pi7PFNi_-eYaY5GjjIbVykLeQlDAimBCNyOiLv9BrPweXw0nKGc0l8LLNFF0oHXyMAbZyCnZUYZ-t5KE0uZQmMy8PpcnbPPP83nnejGB-T_xqKQMXC_BFDflMBrow77P4I8G_zKuGUnoI_3pxgHzLG5tHo767s7EBdJLG2_8E_AkS-L0P</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1321012349</pqid></control><display><type>article</type><title>Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) – a single-center experience</title><source>ScienceDirect Freedom Collection</source><creator>Wolska, A ; Robak, T ; Szmigielska-Kaplon, A ; Pluta, A ; Kopka, P ; Wierzbowska, A</creator><creatorcontrib>Wolska, A ; Robak, T ; Szmigielska-Kaplon, A ; Pluta, A ; Kopka, P ; Wierzbowska, A</creatorcontrib><description>The objective of the study was to evaluate the efficacy of ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). The data of 104 patients transplanted at the Department of Hematology Medical University of Lodz between 2005 and 2008 were analyzed. The cohort was divided into two groups depending on the administered ciprofloxacin prophylaxis. Conditioning regimens did not differ significantly among the groups. Multiple myeloma was the main indication for ASCT in both groups. Ciprofloxacin prophylaxis resulted in a statistically significant reduction of duration of intravenous (IV) antibiotic treatment in the group with prophylaxis (p=0.01). The trend has been observed towards lower prevalence of infectious episodes in the prophylaxis group. Positive blood cultures were similar in both groups with no significant resistance to ciprofloxacin. These data demonstrate that ciprofloxacin prophylaxis is beneficial for patients treated with ASCT following high dose chemotherapy regimen, in terms of the intravenous antibiotics usage. This advantage directly translates into economic benefit and may also induce less bacterial resistance due to less exposure to antibiotics.</description><identifier>ISSN: 1896-1126</identifier><identifier>EISSN: 1898-4002</identifier><identifier>DOI: 10.2478/v10039-012-0004-z</identifier><identifier>PMID: 22366265</identifier><language>eng</language><publisher>Netherlands: Elsevier Urban &amp; Partner Sp. z o.o</publisher><subject>Adult ; Aged ; ASCT ; ciprofloxacin ; Ciprofloxacin - therapeutic use ; Female ; fluoroquinolones ; Fluoroquinolones - therapeutic use ; Humans ; infection ; Male ; melphalan ; Melphalan - therapeutic use ; Middle Aged ; multiple myeloma ; Multiple Myeloma - drug therapy ; prophylaxis ; Retrospective Studies ; Transplantation, Autologous ; Young Adult</subject><ispartof>Advances in medical sciences, 2012-06, Vol.57 (1), p.118-123</ispartof><rights>2012 Medical University of Bialystok</rights><rights>Copyright Versita 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-ac28147a885e98097a6b0e00927a2d8d4b4292956585b0335deac3e56d617c33</citedby><cites>FETCH-LOGICAL-c437t-ac28147a885e98097a6b0e00927a2d8d4b4292956585b0335deac3e56d617c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22366265$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wolska, A</creatorcontrib><creatorcontrib>Robak, T</creatorcontrib><creatorcontrib>Szmigielska-Kaplon, A</creatorcontrib><creatorcontrib>Pluta, A</creatorcontrib><creatorcontrib>Kopka, P</creatorcontrib><creatorcontrib>Wierzbowska, A</creatorcontrib><title>Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) – a single-center experience</title><title>Advances in medical sciences</title><addtitle>Adv Med Sci</addtitle><description>The objective of the study was to evaluate the efficacy of ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). The data of 104 patients transplanted at the Department of Hematology Medical University of Lodz between 2005 and 2008 were analyzed. The cohort was divided into two groups depending on the administered ciprofloxacin prophylaxis. Conditioning regimens did not differ significantly among the groups. Multiple myeloma was the main indication for ASCT in both groups. Ciprofloxacin prophylaxis resulted in a statistically significant reduction of duration of intravenous (IV) antibiotic treatment in the group with prophylaxis (p=0.01). The trend has been observed towards lower prevalence of infectious episodes in the prophylaxis group. Positive blood cultures were similar in both groups with no significant resistance to ciprofloxacin. These data demonstrate that ciprofloxacin prophylaxis is beneficial for patients treated with ASCT following high dose chemotherapy regimen, in terms of the intravenous antibiotics usage. This advantage directly translates into economic benefit and may also induce less bacterial resistance due to less exposure to antibiotics.</description><subject>Adult</subject><subject>Aged</subject><subject>ASCT</subject><subject>ciprofloxacin</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Female</subject><subject>fluoroquinolones</subject><subject>Fluoroquinolones - therapeutic use</subject><subject>Humans</subject><subject>infection</subject><subject>Male</subject><subject>melphalan</subject><subject>Melphalan - therapeutic use</subject><subject>Middle Aged</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>prophylaxis</subject><subject>Retrospective Studies</subject><subject>Transplantation, Autologous</subject><subject>Young Adult</subject><issn>1896-1126</issn><issn>1898-4002</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kbtuFDEUhkcIRC7wADTIEk1SGHyZi0cUUbTiJkWiYHvLa5-dcTRjD7Yn7KbiHSh4P54EbyYghASV_-I7v_9z_qJ4RslLVjbi1Q0lhLeYUIYJISW-fVAcU9EKXBLCHt7pGlPK6qPiJMZrQmpWE_K4OGKM11lXx8X3lZ2C3w5-p7R1KOup3w9qZyPa-oAmlSy4FNHsDITOW9eh3nY9Nj4C0j2MPvUQ1LRHyhmk5uQH3_k5ophgRBqGAaWgXJwG5VI28w6dXX5arc_Rj6_fkEIxOw6Adf4EAoLdBCF_qOFJ8WirhghP79_TYv32zXr1Hl99fPdhdXmFdcmbhJVmgpaNEqKCVpC2UfWGACEtaxQzwpSbkrWsrepKVBvCeWVAaQ5VbWraaM5Pi7PFNi_-eYaY5GjjIbVykLeQlDAimBCNyOiLv9BrPweXw0nKGc0l8LLNFF0oHXyMAbZyCnZUYZ-t5KE0uZQmMy8PpcnbPPP83nnejGB-T_xqKQMXC_BFDflMBrow77P4I8G_zKuGUnoI_3pxgHzLG5tHo767s7EBdJLG2_8E_AkS-L0P</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Wolska, A</creator><creator>Robak, T</creator><creator>Szmigielska-Kaplon, A</creator><creator>Pluta, A</creator><creator>Kopka, P</creator><creator>Wierzbowska, A</creator><general>Elsevier Urban &amp; Partner Sp. z o.o</general><general>Versita</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) – a single-center experience</title><author>Wolska, A ; Robak, T ; Szmigielska-Kaplon, A ; Pluta, A ; Kopka, P ; Wierzbowska, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-ac28147a885e98097a6b0e00927a2d8d4b4292956585b0335deac3e56d617c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>ASCT</topic><topic>ciprofloxacin</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Female</topic><topic>fluoroquinolones</topic><topic>Fluoroquinolones - therapeutic use</topic><topic>Humans</topic><topic>infection</topic><topic>Male</topic><topic>melphalan</topic><topic>Melphalan - therapeutic use</topic><topic>Middle Aged</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>prophylaxis</topic><topic>Retrospective Studies</topic><topic>Transplantation, Autologous</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wolska, A</creatorcontrib><creatorcontrib>Robak, T</creatorcontrib><creatorcontrib>Szmigielska-Kaplon, A</creatorcontrib><creatorcontrib>Pluta, A</creatorcontrib><creatorcontrib>Kopka, P</creatorcontrib><creatorcontrib>Wierzbowska, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>PHMC-Proquest健康医学期刊库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wolska, A</au><au>Robak, T</au><au>Szmigielska-Kaplon, A</au><au>Pluta, A</au><au>Kopka, P</au><au>Wierzbowska, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) – a single-center experience</atitle><jtitle>Advances in medical sciences</jtitle><addtitle>Adv Med Sci</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>57</volume><issue>1</issue><spage>118</spage><epage>123</epage><pages>118-123</pages><issn>1896-1126</issn><eissn>1898-4002</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>The objective of the study was to evaluate the efficacy of ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). The data of 104 patients transplanted at the Department of Hematology Medical University of Lodz between 2005 and 2008 were analyzed. The cohort was divided into two groups depending on the administered ciprofloxacin prophylaxis. Conditioning regimens did not differ significantly among the groups. Multiple myeloma was the main indication for ASCT in both groups. Ciprofloxacin prophylaxis resulted in a statistically significant reduction of duration of intravenous (IV) antibiotic treatment in the group with prophylaxis (p=0.01). The trend has been observed towards lower prevalence of infectious episodes in the prophylaxis group. Positive blood cultures were similar in both groups with no significant resistance to ciprofloxacin. These data demonstrate that ciprofloxacin prophylaxis is beneficial for patients treated with ASCT following high dose chemotherapy regimen, in terms of the intravenous antibiotics usage. This advantage directly translates into economic benefit and may also induce less bacterial resistance due to less exposure to antibiotics.</abstract><cop>Netherlands</cop><pub>Elsevier Urban &amp; Partner Sp. z o.o</pub><pmid>22366265</pmid><doi>10.2478/v10039-012-0004-z</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1896-1126
ispartof Advances in medical sciences, 2012-06, Vol.57 (1), p.118-123
issn 1896-1126
1898-4002
language eng
recordid cdi_proquest_miscellaneous_1020828878
source ScienceDirect Freedom Collection
subjects Adult
Aged
ASCT
ciprofloxacin
Ciprofloxacin - therapeutic use
Female
fluoroquinolones
Fluoroquinolones - therapeutic use
Humans
infection
Male
melphalan
Melphalan - therapeutic use
Middle Aged
multiple myeloma
Multiple Myeloma - drug therapy
prophylaxis
Retrospective Studies
Transplantation, Autologous
Young Adult
title Ciprofloxacin prophylaxis for patients undergoing high-dose chemotherapy and autologous stem cell transplantation (ASCT) – a single-center experience
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T08%3A19%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ciprofloxacin%20prophylaxis%20for%20patients%20undergoing%20high-dose%20chemotherapy%20and%20autologous%20stem%20cell%20transplantation%20(ASCT)%20%E2%80%93%20a%20single-center%20experience&rft.jtitle=Advances%20in%20medical%20sciences&rft.au=Wolska,%20A&rft.date=2012-06-01&rft.volume=57&rft.issue=1&rft.spage=118&rft.epage=123&rft.pages=118-123&rft.issn=1896-1126&rft.eissn=1898-4002&rft_id=info:doi/10.2478/v10039-012-0004-z&rft_dat=%3Cproquest_cross%3E1020828878%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c437t-ac28147a885e98097a6b0e00927a2d8d4b4292956585b0335deac3e56d617c33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1321012349&rft_id=info:pmid/22366265&rfr_iscdi=true